Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Amish lethal microcephaly is a very rare syndrome characterized by extreme microcephaly and early death, within the first year.
Features include always present findings: Axial hypotonia, Cerebellar vermis hypoplasia, Sloping forehead, and Poor suck and others. 19 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 3 | Axial hypotonia, Flexion contracture, Damage to the optic nerve (optic atrophy) |
SLC25A19 function has not been fully characterized.
Amish lethal microcephaly is associated with mutations in the SLC25A19 gene on chromosome 17.
SLC25A19-related thiamine metabolism dysfunction (SLC25A19 deficiency) is characterized by two phenotypes: Amish lethal microcephaly and thiamine metabolism dysfunction syndrome 4 (THMD-4).
Amish lethal microcephaly should be suspected in probands with the following findings:
Severe congenital microcephaly
Developmental delay
No approved treatments are currently available for Amish lethal microcephaly. The disease remains an area of unmet medical need.
No clinical practice guidelines for SLC25A19-related thiamine metabolism dysfunction (SLC25A19 deficiency) have been published. Evaluation Following Initial Diagnosis To establish the extent of disease in an individual diagnosed with SLC25A19 deficiency, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with SLC25A19-Related Thiamine Metabolism Dysfunction
To monitor existing manifestations, the individual's response to targeted therapy and supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended.
Table 5.
Recommended Surveillance for Individuals with SLC25A19-Related Thiamine Metabolism Dysfunction
System/Concern | Evaluation | Frequency
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 4:44 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Amish lethal microcephaly
3 |
Irritability, Cerebral visual impairment, Sudden, brief involuntary muscle jerks (myoclonus) |
Eyes | 2 | Cerebral visual impairment, Damage to the optic nerve (optic atrophy) |
Digestive system | 1 | Enlarged liver (hepatomegaly) |
Growth and development | 1 | Failure to thrive |
Head and neck | 1 | Primary microcephaly |
Arms and legs | 1 | Limb hypertonia |
The two phenotypes observed in SLC25A19-related thiamine metabolism dysfunction (SLC25A19 deficiency) are Amish lethal microcephaly and thiamine metabolism dysfunction syndrome 4 (THMD-4).
Amish lethal microcephaly is characterized by severe congenital microcephaly, developmental delay, seizures, 2-oxoglutaric aciduria, and often premature death. The phenotype shows little variability . Congenital microcephaly has been reported in all affected infants. Head circumference is typically more than two standard deviations (SD) below the mean and occasionally more than six SD below the mean, with an extremely underdeveloped cranial vault as a result of the small brain size.
Source: GeneReviews — "SLC25A19-Related Thiamine Metabolism Dysfunction"
Seizures
Lactic acidosis
Highly elevated (≥10-fold increase) levels of acid 2-ketoglutarate on urine organic acids
THMD-4 should be suspected in probands with the following findings:
Source: GeneReviews — "SLC25A19-Related Thiamine Metabolism Dysfunction"
Amish Lethal Microcephaly Microcephaly has a wide variety of causative factors. It can be syndromic or isolated, environmental or genetic, congenital or acquired . Metabolic testing (including urine organic acids, plasma amino acids, lactate, pyruvate, and electrolytes) is indicated for all children with congenital microcephaly. Further specific evaluations are performed as indicated based on the results of this testing. The primary microcephalies are a group of rare, phenotypically and etiologically heterogeneous disorders of brain growth characterized by (1) a head circumference two or more standard deviations (SD) below the mean at birth and three or more SD below the mean by age one year, and (2) mild-to-severe intellectual disability. Additional clinical or neuroimaging features can be associated. Most primary microcephalies are inherited in an autosomal recessive manner. To date, pathogenic variants in more than 100 genes are known to cause primary microcephaly (for review, see ). (See also WDR62 Primary Microcephaly and ASPM Primary Microcephaly.) The degree of microcephaly is much greater in Amish lethal microcephaly than in any of these other genetically defined microcephaly syndromes. Additionally, 2-ketoglutaric aciduria is a good clue for the diagnosis of Amish lethal microcephaly, as 2-ketoglutaric aciduria has not been reported as a finding in other genetically defined microcephaly syndromes. Alpha-ketoglutarate. Among other genetic malformation syndromes, a similar level of urinary 2-ketoglutarate is also characteristic of DOORS (deafness, onychodystrophy, osteodystrophy, intellectual disability [formerly known as mental retardation], seizures) syndrome, caused by biallelic pathogenic variants in TBC1D24. Microcephaly is noted in one third of individuals with DOORS syndrome. (See TBC1D24-Related Disorders.) Thiamine Metabolism Dysfunction Syndrome 4 Table 2. Genes of Interest in the Differential Diagnosis of Thiamine Metabolism Dysfunction Syndrome 4
Gene | Disorder | MOI | Clinical Characteristics/ Comment |
|---|---|---|---|
Primary mitochondrial disorders | ARADXLMat | levels of urinary 2-ketoglutarate are common in wide variety of disorders of mitochondrial dysfunction, incl those caused by mutation of both mtDNA nuclear DNA genes. | — |
BCKDHABCKDHBDBTIVDMCEEMMAAMMABMMADHCMMUTPCCAPCCB2 | Organic acid disorders (e.g., isolated methylmalonic acidemia, maple syrup urine disease, propionic acidemia) | AR | Major clinical features are developmental delay, seizures, lethargy, coma, hypotonia, vomiting, poor weight gain, growth deficiency, hepatomegaly, respiratory distress, cardiac dysfunction, hypoglycemia, acidosis. DLD |
Dihydrolipoamide dehydrogenase deficiency | AR | levels of urinary alpha-ketoglutarate may be seen in persons w/pathogenic variants in the alpha-ketoglutarate dehydrogenase complex. | — |
NUP62 | Infantile striatonigral degeneration (OMIM 271930) | ... | — |
Source: GeneReviews — "SLC25A19-Related Thiamine Metabolism Dysfunction"
Genetic testing for SLC25A19 is available. Testing is considered confirmatory for diagnosis.
System/Concern | Evaluation | Comment |
|---|---|---|
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education Gastrointestinal/ |
Feeding | Gastroenterology/ nutrition/ feeding team eval | To incl eval of aspiration risk nutritional status; Consider eval for gastrostomy tube placement in persons w/dysphagia /or aspiration risk. |
Genetic counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of SLC25A19 deficiency to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with SLC25A19-Related Thiamine Metabolism Dysfunction Manifestation/Concern | Treatment | Considerations/Other Acute encephalopathic episodes |
Dystonia | Symptomatic treatment incl administration of trihexyphenidyl or L-dopa | Spasticity |
Intellectual disability | See . | — |
Infection/Fever | Routine childhood illnesses should be managed to minimize acidosis assoc w/acute illnesses. | Family/Community |
Source: GeneReviews — "SLC25A19-Related Thiamine Metabolism Dysfunction"
Avoidance of contact with individuals with communicable respiratory diseases is appropriate. Avoid sodium valproate as an anti-seizure medication.
Source: GeneReviews — "SLC25A19-Related Thiamine Metabolism Dysfunction"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "SLC25A19-Related Thiamine Metabolism Dysfunction"
View trials for Amish lethal microcephaly
| Monitor developmental progress educational needs. | At each visit
| • Measurement of growth parameters
Eval of nutritional status safety of oral intake
| Physical medicine, OT/PT assessment of mobility, self-help skills
| Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning).
OT = occupational therapy; PT = physical therapy
Source: GeneReviews — "SLC25A19-Related Thiamine Metabolism Dysfunction"
Phenotype severity distribution: 15 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
AI-curated news mentioning Amish lethal microcephaly
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.